BCR-ABL tyrosine kinase (BCR-ABL)

The BCR-ABL tyrosine kinase is a fusion protein resulting from a reciprocal translocation between chromosomes 9 and 22, creating what is known as the Philadelphia chromosome. This genetic abnormality leads to the fusion of the BCR and ABL1 genes, producing a constitutively active tyrosine kinase that drives the development of chronic myelogenous leukemia. The protein functions as a non-receptor tyrosine kinase that phosphorylates various substrate proteins, activating multiple signaling pathways that promote cell proliferation and survival. The development of tyrosine kinase inhibitors targeting BCR-ABL has revolutionized the treatment of CML, transforming it from a fatal disease to a manageable chronic condition for many patients.

Other names

Philadelphia chromosome proteinp210 BCR-ABL

Tyrosine kinase inhibition, ATP-competitive binding, Inhibition of BCR-ABL autophosphorylation